2021
Corticosteroid use in chronic dermatologic disorders and osteoporosis
Lupsa BC, Insogna KL, Micheletti RG, Caplan A. Corticosteroid use in chronic dermatologic disorders and osteoporosis. International Journal Of Women's Dermatology 2021, 7: 545-551. PMID: 35024411, PMCID: PMC8721058, DOI: 10.1016/j.ijwd.2021.07.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsGlucocorticoid-induced osteoporosisGlucocorticoid therapyChronic dermatologic disordersUse of glucocorticoidsSerious side effectsGlucocorticoid useCorticosteroid useBone healthBone lossDermatologic disordersSide effectsPatientsOsteoporosisGlucocorticoidsTherapyCase vignettesRiskComplicationsDermatologists
2018
Chapter 83 The Hypocalcemic Disorders
Gafni R, Insogna K, Carpenter T. Chapter 83 The Hypocalcemic Disorders. 2018, 527-547. DOI: 10.1016/b978-0-12-809963-6.00083-3.ChaptersHypocalcemic disordersParathyroid hormoneVitamin DHypocalcemic conditionsLong-term managementPTH secretionChronic hypocalcemiaNarrow normal rangeCalciotropic hormonesFunctional etiologyClinical manifestationsVitamin D.PTH actionHomeostatic disturbancesNormal rangePhysiologic consequencesClinical scenariosHypocalcemiaMetabolic activationDisordersMolecular actionsEtiologyHormoneFunctional mechanismsTherapy
2016
Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz therapy among HIV-infected individuals
Hsieh E, Fraenkel L, Han Y, Xia W, Insogna K, Yin M, Zhu T, Cheng X, Li T. Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz therapy among HIV-infected individuals. Bone Abstracts 2016 DOI: 10.1530/boneabs.5.op20.Peer-Reviewed Original ResearchLongitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz therapy among HIV-infected individuals
Hsieh E, Fraenkel L, Han Y, Xia W, Insogna K, Yin M, Zhu T, Cheng X, Li T. Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz therapy among HIV-infected individuals. Bone Abstracts 2016 DOI: 10.1530/boneabs.5.p337.Peer-Reviewed Original Research
2010
Circulating Levels of Soluble Klotho and FGF23 in X-Linked Hypophosphatemia: Circadian Variance, Effects of Treatment, and Relationship to Parathyroid Status
Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, Olear E, Gundberg CM. Circulating Levels of Soluble Klotho and FGF23 in X-Linked Hypophosphatemia: Circadian Variance, Effects of Treatment, and Relationship to Parathyroid Status. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e352-e357. PMID: 20685863, PMCID: PMC2968736, DOI: 10.1210/jc.2010-0589.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedBone Density Conservation AgentsCalcitriolChildCircadian RhythmEnzyme-Linked Immunosorbent AssayFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGenetic Diseases, X-LinkedGlucuronidaseHumansKlotho ProteinsMaleMiddle AgedParathyroid HormonePhosphatesVitamin DConceptsSerum KlothoSerum FGF23Higher klotho levelsHospital research unitRenal phosphate handlingAcademic medical centerEffect of treatmentFibroblast growth factorKlotho levelsPTH secretionMedical therapySoluble KlothoDihydroxyvitamin DFGF23 regulationPhosphate handlingMedical CenterFGF23KlothoXLHCircadian variationGrowth factorPTHAdultsHypophosphatemiaTherapy
2008
Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum
Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G. Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum. Cell 2008, 135: 825-837. PMID: 19041748, PMCID: PMC2614332, DOI: 10.1016/j.cell.2008.09.059.Peer-Reviewed Original ResearchConceptsBone massBone formationLrp5-deficient miceSerotonin blood levelsExpression of TPH1High bone massOsteoblast-specific disruptionRate-limiting biosynthetic enzymeBone lossEnterochromaffin cellsBlood levelsSerotonin synthesisPotential therapyBone remodelingWnt coreceptorSerotoninLRP5Function mutationsDuodenumTPH1Independent mannerOsteoporosisTherapyBiosynthetic enzymesMice
1997
Estrogen Replacement Therapy: New Options, Continuing Concerns-Reply
Insogna K, Concato J, Henrich J. Estrogen Replacement Therapy: New Options, Continuing Concerns-Reply. JAMA 1997, 277: 1516-1517. DOI: 10.1001/jama.1997.03540430028020.Peer-Reviewed Original ResearchBreast cancer riskBreast cancerBone densityCancer riskLow endogenous estrogen levelsHigh endogenous estrogenEstrogen replacement therapyEndogenous estrogen levelsTreatment of osteoporosisHigher bone densityAfrican American womenEstrogen levelsReplacement therapyExogenous estrogenEstrogen influenceEndogenous estrogensLower riskCancerWomenOsteoporosisRiskEstrogenNew optionsTherapyBMD
1989
Trichlormethiazide and Oral Phosphate Therapy in Patients with Absorptive Hypercalciuria
Insogna K, Ellison A, Burtis W, Sartori L, Lang R, Broadus A. Trichlormethiazide and Oral Phosphate Therapy in Patients with Absorptive Hypercalciuria. Journal Of Urology 1989, 141: 269-273. PMID: 2913343, DOI: 10.1016/s0022-5347(17)40737-3.Peer-Reviewed Original ResearchConceptsOral phosphate therapyDihydroxyvitamin D levelsAbsorptive hypercalciuriaUrinary calciumParathyroid functionPhosphate therapyPhosphate administrationD levelsOral phosphate administrationRenal phosphate thresholdTreatment urinary calciumStudy 36 patientsPre-treatment valuesTrichlormethiazide treatmentCalcium excretionDihydroxyvitamin DBiochemical abnormalitiesSecond drugPharmacological meansStudy subjectsHypercalciuriaPatientsTherapyPer cent decreaseTreatment